Artificial Tears Forecast till 2030

List of Tables

Market Overview

The rising pervasiveness of dry eye infection and eye irritation, and the rising inclination for additive free items are driving market development.

The rising interest for additive free artificial tears inferable from the results of additives including eye disturbance, particularly for moderate or serious dry eyes is driving the artificial tears market. Moreover, the rising number of item dispatches by vital participants is expanding item separation and consequently driving market development. For example, In January 2022, Alcon (Switzerland) sent off Systane complete additive free oil eye drops in the European market. Similarly, in October 2019, Allergan, Inc. (Auxiliary of AbbVie, US) sent off the Invigorate Relieva grease eye drop product offering, an extension of the Revive portfolio. The product offering included Revive Relieva PF (additive free) multidose.

Moreover, expanding item dispatches for additive free items is driving the artificial tears market. Besides, propels in bundling plan and conveyance systems for additive free eye drops to forestall tainting are further driving the market for artificial tears market. Hence, expanding inclination for additive free items is driving the market development.

Market Segmentation

Based on type, the Artificial Tears Market is divided into segments such as cellulose, glycerin, propylene glycol, and polyethylene glycol. The market is separated into eye drops, ointments, and sprays based on the mechanism of delivery.

The dry eye condition, allergies, infections, and other conditions are categorized under the application sector of the artificial tears market. Hospital pharmacies, drug stores, retail pharmacies, and internet pharmacies are all part of the distribution system.

Regional Insights

The North America artificial tears market represented the largest market owing to the of the great commonness of dry eye sickness, the presence of market vital participants, and the developing interest for contact focal points in the region Dry eye illness is exceptionally far reaching in the US, influencing a huge level of the populace, especially those beyond 50 years old.

Europe artificial tears market represents the second-largest market owing to the great pervasiveness of ophthalmic issues, expanding utilization of cutting-edge eye drops, and a quickly flooding maturing populace. further, UK artificial tears market was credited to hold the biggest market share, and the France artificial tears market is supposed to quickest developing market in the European region.

The Asia-Pacific artificial tears market is supposed to develop at a fast rate during the review period. This is because of the solid likely persistent populace, rising consciousness of visual illnesses, and expanding medical services consumption in the Asia-Pacific region. Besides, China artificial tears market is supposed to hold the biggest market offer, and India artificial tears market is normal quickest developing market in the Asia-Pacific region.

Major Players

Key Companies in the worldwide Artificial Tears Market are Johnson and Johnson Vision Care (US), Allergan plc (Ireland), Alcon Plc (Switzerland), Bausch & Lomb Incorporated (Canada), Santen, Inc (Japan), URSAPHARM Arzneimittel GmbH (Germany), ROHTO Pharmaceutical CO., LTD (Japan), Similasan Corporation (US), Ocusoft (US), and Nicox (France).

Product Code: MRFR/HC/10538-CR

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 MARKET STRUCTURE
2.4 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW
4.2 DRIVERS
- 4.2.1 INCREASING PREVALENCE OF DRY EYE DISEASE AND EYE INFLAMMATION
- 4.2.2 RISING PREFERENCE FOR PRESERVATIVE-FREE PRODUCTS
4.3 RESTRAINTS
- 4.3.1 SIDE-EFFECTS AND ALLERGIC REACTIONS
4.4 OPPORTUNITIES
- 4.4.1 ADVANCEMENT IN DIAGNOSTICS FOR DRY EYE DISEASE

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D
- 5.1.2 MANUFACTURING
- 5.1.3 DISTRIBUTION AND SALES
- 5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE ARTIFICIAL TEARS MARKET
- 5.3.1 IMPACT ON SUPPLY CHAIN
- 5.3.2 IMPACT ON MANUFACTURERS
5.4 PRICING ANALYSIS

6 GLOBAL ARTIFICIAL TEARS MARKET, BY TYPE

6.1 OVERVIEW
6.2 POLYETHYLENE GLYCOL
6.3 PROPYLENE GLYCOL
6.4 CELLULOSE
6.5 GLYCERIN
6.6 OTHERS

7 GLOBAL ARTIFICIAL TEARS MARKET, BY DELIVERY MODE

7.1 OVERVIEW
7.2 EYE DROPS
7.3 OINTMENTS
7.4 SPRAYS

8 GLOBAL ARTIFICIAL TEARS MARKET, BY APPLICATION

8.1 OVERVIEW
8.2 DRY EYE SYNDROME
8.3 ALLERGIES AND INFECTIONS
8.4 OTHERS

9 GLOBAL ARTIFICIAL TEARS MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW
9.2 HOSPITAL PHARMACIES
9.3 DRUG STORES
9.4 RETAIL PHARMACIES
9.5 ONLINE PHARMACIES

10 GLOBAL ARTIFICIAL TEARS MARKET, BY REGION

10.1 OVERVIEW
10.2 NORTH AMERICA
- 10.2.1 US
- 10.2.2 CANADA
10.3 EUROPE
- 10.3.1 GERMANY
- 10.3.2 UK
- 10.3.3 FRANCE
- 10.3.4 ITALY
- 10.3.5 SPAIN
- 10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
- 10.4.1 JAPAN
- 10.4.2 CHINA
- 10.4.3 INDIA
- 10.4.4 AUSTRALIA
- 10.4.5 SOUTH KOREA
- 10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
- 10.5.1 MIDDLE EAST
- 10.5.2 AFRICA
- 10.5.3 LATIN AMERICA

11 COMPETITIVE LANDSCAPE

11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.7.1 PRODUCT LAUNCH
- 11.7.2 COLLABORATION
- 11.7.3 AGREEMENT
- 11.7.4 ACQUISITION
- 11.7.5 PARTNERSHIP
11.8 MAJOR PLAYERS FINANCIAL MATRIX
- 11.8.1 SALES (USD BILLION), 2022
- 11.8.2 R&D (USD BILLION), 2022

12 COMPANY PROFILES

12.1 JOHNSON AND JOHNSON VISION CARE
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 PRODUCTS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
12.2 ALLERGAN PLC
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 PRODUCTS OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGIES
12.3 ALCON PLC
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 PRODUCTS OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 SWOT ANALYSIS
- 12.3.6 KEY STRATEGIES
12.4 BAUSCH & LOMB INCORPORATED
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 SWOT ANALYSIS
- 12.4.6 KEY STRATEGIES
12.5 SANTEN, INC.
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 SWOT ANALYSIS
- 12.5.6 KEY STRATEGIES
12.6 URSAPHARM ARZNEIMITTEL GMBH
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 KEY STRATEGIES
12.7 ROHTO PHARMACEUTICAL CO., LTD.
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 KEY STRATEGIES
12.8 SIMILASAN CORPORATION
- 12.8.1 COMPANY OVERVIEWS
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 KEY STRATEGIES
12.9 OCUSOFT
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
12.10 NICOX
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 KEY STRATEGIES

13 APPENDIX

13.1 REFERENCES
13.2 RELATED REPORTS